《Circana：2024Q3-2025Q1美国药品渠道市场格局报告（英文版）（44页）.pdf》由会员分享，可在线阅读，更多相关《Circana：2024Q3-2025Q1美国药品渠道市场格局报告（英文版）（44页）.pdf（44页珍藏版）》请在三个皮匠报告上搜索。

1、Circana,LLC|For public use1Copyright 2025 Circana,LLC(“Circana”).All rights reserved.Circana,the Circana logo,and the names of Circana products and services are trademarks of Circana.All other trademarks are the property of their respective owners.U.S.Drug Channel Landscape May 2025Q3 2024 Q1 2025Ci

2、rcana,LLC|For public use2 2Executive SummaryIn this report,we follow up on trends identified in previous drug channel analyses and examine how these trends compare to the broader multioutlet and convenience channel landscape.In Q1 2025,drug channel salescontinue to lag the multioutlet market as cons

3、umers continue to shop other channels to save time and money.Consumers continue to seek wellness options that are more convenient and cost-efficient.The drug channel has an opportunity to drive more quick trips and dollars from the convenience channel and expand pharmacy operations.Drug channel doll

4、ar sales declined 5.5%in Q1 2025.The number of buyers purchasing in the drug channel declined less in Q1 2025 vs.Q4 2024 but is still declining as consumers continued to shop more at other channels.Average price inflation has increased in the health and beauty departments,which account for 66%of tot

5、al dollar sales in the drug channel.The frequency of promotions remained high through 2024 and into 2025.Lift saw gains toward the end of 2024 and into 2025.In the drug channel,private label sales declined vs.YA across most departments,whereas in MULO+w/Convenience,private label has grown across all

6、 departments.Beauty department at drug declined 6%vs.YA,with the highest sales in skincare and cosmetics.Quick trips and special purpose trips are the primary trip types in drug.Consumers are shopping less in the drug channel,but the drug channel is important to consumers.Store closures continue,but